Overview

Study Elesclomol Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Status:
Unknown status
Trial end date:
2014-08-01
Target enrollment:
Participant gender:
Summary
This is a phase 1 study to test the safety of escalating doses of elesclomol sodium given to patients with advanced myeloid leukemia.
Phase:
Phase 1
Details
Lead Sponsor:
Synta Pharmaceuticals Corp.